SHINE Technologies
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $11.4m | Late VC | |
N/A | Debt | ||
* | $150k | Grant | |
N/A | $11.5m | Early VC | |
$10.0m | Grant | ||
N/A | $29.3m | Debt | |
N/A | $30.0m | Series B | |
N/A | $18.1m | Series C | |
$80.0m | Series C | ||
$150m | Series C | ||
* | $70.0m Valuation: $750m | Late VC | |
* | $32.0m | Grant | |
Total Funding | €376m |
Recent News about SHINE Technologies
EditFounded in 2005 by Greg Piefer, SHINE is a pioneering company focused on harnessing the potential of fusion technology to create a safer, healthier, and cleaner world. Operating in the nuclear technology sector, SHINE serves a diverse range of clients including those in the medical, industrial, and security industries. The company’s core business model revolves around the production of neutrons through its innovative fusion-based technology, which is used for advanced industrial inspection and medical isotope production. This technology not only aids in contraband detection but also plays a crucial role in medical therapeutics by producing isotopes used in diagnostic imaging and cancer treatment. SHINE generates revenue by providing these specialized neutron production services to its clients, leveraging its four-phase pathway to fusion energy production to ensure a commercially practical and growth-oriented approach. The company is also actively involved in expanding its market applications and has appointed industry veterans to its board to guide its strategic direction.
Keywords: fusion technology, neutron production, medical isotopes, industrial inspection, contraband detection, nuclear energy, therapeutic isotopes, diagnostic imaging, cancer treatment, strategic growth.